FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Harvey Jimmie
   2. Issuer Name and Ticker or Trading Symbol
Fortress Biotech, Inc. [FBIO] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O FORTRESS BIOTECH, INC., 2 GANSEVOORT STREET, 9TH FLOOR		 3. Date of Earliest Transaction (Month/Day/Year)
01/01/2017
(Street)

NEW YORK, NY 10014		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001               50,000 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Deferred Restricted Stock Units $ 0 (1) 01/01/2017   A   16,666     (1)   (1) Common Stock 16,666 $ 0 (2) 33,332 D  
Deferred Restricted Stock Units $ 0 (3) 01/01/2017   A   16,666     (3)   (3) Common Stock 16,666 $ 0 (2) 33,332 D  
Options to purchase Common Stock $ 1.37               (4) 10/05/2020 Common Stock 25,000   25,000 D  
Options to purchase Common Stock $ 6.25               (5) 02/10/2022 Common Stock 15,000   15,000 D  
Options to purchase Common Stock $ 7.42               (6) 02/07/2023 Common Stock 15,000   15,000 D  
Options to purchase Common Stock $ 2.1               (7) 12/19/2023 Common Stock 30,000   30,000 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Harvey Jimmie
C/O FORTRESS BIOTECH, INC.
2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK, NY 10014		   X      

Signatures

 /s/ S. Halle Vakani, Attorney-in-Fact   01/24/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan.
(2) Upon the vesting of RSUs, the Reporting Person deferred the receipt of 16,666 shares of common stock and received instead 16,666 shares of deferred RSUs.
(3) The Reporting Person was granted RSUs for service on the Strategic Transaction Committee in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Plan. Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan.
(4) One-third of the shares vested on each of October 5, 2011, 2012 and 2013.
(5) One-third of the shares vested on each of February 10, 2013, 2014 and 2015.
(6) One-third of the shares vested on each of February 7, 2014, 2015 and 2016.
(7) One-third of the shares vested on each of December 19, 2014, 2015 and 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.